Beam Therapeutics Inc. (BEAM): Depreciation & Amortization
$22.29M
Year ended 2025-12-31
$22.24M
Trailing 12 months to 2026-06-30
+16.4%
3-year compound annual growth
+36.3%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $22.29M | +1.7% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $21.93M | +9.6% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $20.01M | +41.5% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $14.15M | +89.9% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $7.45M | +57.4% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $4.74M | +35.2% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $3.50M | n/a | 2022-02-28, From 2019-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $22.29M | +1.7% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $2.12M | -58.1% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $58.99M | -6.4% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $15.62M | -3.7% |
| Agenus Inc (AGEN) | 2025-12-31 | $10.00M | -25.1% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $15.53M | -11.6% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $7.32M | +1.5% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $4.69M | +0.9% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $8.58M | -3.1% |
Compare BEAM, ATRA, DNA, RGNX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗